Guided Therapeutics (GTHP) & The Competition Financial Comparison

Insider & Institutional Ownership

9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 44.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by insiders. Comparatively, 15.1% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Guided Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.67
Guided Therapeutics Competitors	$970.72 million	$81.05 million	9.85

Guided Therapeutics’ peers have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Guided Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-298.31%	-84.84%	-26.40%

Risk and Volatility

Guided Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ peers have a beta of 0.87, meaning that their average share price is 13% less volatile than the S&P 500.

Summary

Guided Therapeutics peers beat Guided Therapeutics on 6 of the 9 factors compared.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.